| Targets |
Braylin targets phosphodiesterase-4 (PDE4), a key enzyme involved in the degradation of cyclic AMP (cAMP). By inhibiting PDE4, Braylin increases intracellular cAMP levels, which in turn modulates inflammatory responses. It also activates the glucocorticoid receptor and inhibits the transcriptional activity of NF-κB, contributing to its anti-inflammatory profile.
|
|---|---|
| ln Vitro |
In vitro, Braylin has been shown to exert anti-inflammatory and immunomodulatory effects. Studies have demonstrated its ability to inhibit PDE4 activity. The compound's activation of the glucocorticoid receptor and inhibition of NF-κB transcriptional activity are key mechanisms for its observed anti-inflammatory properties. It is a potent compound with potential for treating immunoinflammatory diseases.
|
| ln Vivo |
In vivo, Braylin is expected to exhibit anti-inflammatory and immunomodulatory activities, consistent with its in vitro profile. As a PDE4 inhibitor, it may be effective in animal models of inflammation and immune disorders. Its ability to act as a glucocorticoid receptor ligand could provide a synergistic effect, potentially offering an alternative to traditional steroid therapies.
|
| Enzyme Assay |
In vitro enzyme assays for PDE4 inhibition involve incubating Braylin with the PDE4 enzyme and a substrate such as cAMP in a suitable buffer. The enzymatic activity is measured by quantifying the amount of hydrolyzed product (AMP) using radiometric, fluorescence-based, or HPLC methods. The compound's IC₅₀ is determined from dose-response curves to assess its potency.
|
| Cell Assay |
For in vitro cell assays, immune cells such as macrophages or lymphocytes are cultured and treated with Braylin. The production of pro-inflammatory cytokines (e.g., TNF-α, IL-6) is measured by ELISA. The compound's effects on NF-κB activation are assessed by luciferase reporter assays or by measuring the nuclear translocation of the p65 subunit. Cell viability is assessed by MTT assay.
|
| Animal Protocol |
For in vivo animal studies, Braylin is typically administered to rodents via oral gavage or intraperitoneal injection in models of inflammation, such as carrageenan-induced paw edema or experimental autoimmune encephalomyelitis. Inflammatory markers, cytokine levels, and immune cell infiltration are measured to assess the compound's efficacy.
|
| ADME/Pharmacokinetics |
Braylin (MW ~258.27) has the molecular formula C₁₅H₁₄O₄. The compound is typically stored as a powder at -20°C. It is soluble in DMSO and other organic solvents. Its stability under various conditions is well-characterized for research applications. As a coumarin derivative, it has favorable drug-like properties.
|
| Toxicity/Toxicokinetics |
Braylin is for research use only. No specific toxicity data are available. As a PDE4 inhibitor and glucocorticoid receptor ligand, its toxicity profile is expected to be related to its immunomodulatory activity. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Braylin has reportedly been found in Cedrelopsis grevei, Geleznowia verrucosa, and other organisms with available data.
Braylin (CAS# 6054-10-0) is a natural product and research compound with potent anti-inflammatory and immunomodulatory properties. It has not been approved as a therapeutic drug. The compound is used in research on immunoinflammatory diseases, asthma, and chronic obstructive pulmonary disease (COPD). It is a valuable tool for studying PDE4 biology and glucocorticoid receptor signaling. |
| Exact Mass |
258.089
|
|---|---|
| CAS # |
6054-10-0
|
| PubChem CID |
618370
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
441.2±45.0 °C at 760 mmHg
|
| Flash Point |
198.5±28.8 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.570
|
| LogP |
3.15
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
437
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UOFNVZWWIXXTMZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14O4/c1-15(2)7-6-10-13-9(4-5-12(16)18-13)8-11(17-3)14(10)19-15/h4-8H,1-3H3
|
| Chemical Name |
6-methoxy-8,8-dimethylpyrano[2,3-f]chromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
